Literature DB >> 3630900

Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients.

M M Applefeld, K A Newman, F J Sutton, W P Reed, D S Roffman, B S Talesnick, W R Grove.   

Abstract

Dobutamine (and dopamine) are potent positive inotropic drugs which are frequently given to treat decompensated congestive heart failure. This study reports on the use of ambulatory dobutamine (and dopamine) infusions in 21 outpatients with advanced congestive heart failure. Each patient was initially hospitalized, and hemodynamic and clinical efficacy to dobutamine (and dopamine) was assessed. These 21 patients were carefully selected from a larger population of approximately 40 patients referred for this therapy. Chronic venous access was established and a drug infusion pump was supplied. Patients and family members were trained in the use of these devices. Eleven patients were treated with intermittent dobutamine infusions for 48 consecutive hours weekly, six patients with continuous (i.e., 24 hours daily) dobutamine infusions, and four patients with continuous, daily dobutamine and dopamine infusions. Significant (p less than 0.001) increases in cardiac index (1.8 +/- 0.6 to 2.7 +/- 0.7 L/min/m2) occurred during the initial dobutamine titrations. Functional classification (3.8 +/- 0.4 to 2.8 +/- 0.7) also improved significantly (p less than 0.01) during the 1.8 to 24 (mean 7.8) months of outpatient infusion therapy with dobutamine (and dopamine). Complications during outpatient therapy included drug tolerance (two instances), infection (two with bacteremias, eight with exit site infections), drug extravasation (three instances), and pump malfunction (two instances). Twenty patients have died: eleven from heart failure, four suddenly (one of them 9 months after dobutamine was stopped), and five from noncardiac causes. Our data suggest that outpatient dobutamine (and dopamine) infusions may be an effective form of therapy for selected patients with severe congestive failure who are refractory to more conventional treatment or who are awaiting cardiac transplantation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3630900     DOI: 10.1016/0002-8703(87)90757-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

1.  The effects of dopamine and a low protein diet on glomerular filtration rate and renal plasma flow in the aged kidney.

Authors:  G J Fancourt; V S Asokan; S C Bennett; J Walls; C M Castleden
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Chronic inotropic therapy in end-stage heart failure.

Authors:  Paul J Hauptman; Peter Mikolajczak; Anil George; Clinton J Mohr; Robert Hoover; Jason Swindle; Mark A Schnitzler
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

Review 3.  Treatment of end stage dilated cardiomyopathy.

Authors:  J B O'Connell; C K Moore; H C Waterer
Journal:  Br Heart J       Date:  1994-12

4.  The acute effects of a single dopamine infusion in elderly patients with congestive cardiac failure.

Authors:  T Robinson; S Gariballa; G Fancourt; J Potter; M Castleden
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

Review 5.  Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure.

Authors:  Abhishek Jaiswal; Vinh Q Nguyen; Thierry H Le Jemtel; Keith C Ferdinand
Journal:  World J Cardiol       Date:  2016-07-26

6.  Renal Function and Outcomes With Use of Left Ventricular Assist Device Implantation and Inotropes in End-Stage Heart Failure: A Retrospective Single Center Study.

Authors:  Sean Verma; Emmanuel Bassily; Shane Leighton; Rahul Mhaskar; Igor Sunjic; Angel Martin; Nancy Rihana; Tambi Jarmi; Claude Bassil
Journal:  J Clin Med Res       Date:  2017-05-22

7.  Continuous Intravenous Milrinone Therapy in Pediatric Outpatients.

Authors:  Michelle Curley; Jill Liebers; Roy Maynard
Journal:  J Infus Nurs       Date:  2017 Mar/Apr

Review 8.  Inotropes do not increase mortality in advanced heart failure.

Authors:  Maya Guglin; Marc Kaufman
Journal:  Int J Gen Med       Date:  2014-05-20

9.  Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure.

Authors:  Pieter Martens; Jan Vercammen; Wendy Ceyssens; Linda Jacobs; Evert Luwel; Herwig Van Aerde; Peter Potargent; Monique Renaers; Matthias Dupont; Wilfried Mullens
Journal:  ESC Heart Fail       Date:  2018-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.